Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Academy: 200-day line · RSI
About the company
Charles River Laboratories is a service provider for pharmaceutical and biotech companies. It conducts preclinical safety studies for new drug candidates, supplies research animals and offers testing services for drug manufacturing. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Contract research (biology and medicine) · Wilmington, USAfull fact sheet
Charles River Laboratories sees itself as a partner for non-clinical drug development, having grown out of laboratory animal medicine. Its offering ranges from research models and drug discovery to safety testing under GLP and non-GLP conditions. The Manufacturing Solutions segment comprises Microbial Solutions for microbial quality control and Biologics Solutions for testing biologic drugs. This includes endotoxin tests for injectable products and medical devices based on an extract from horseshoe crabs. Its customers include pharmaceutical companies, biotech firms, contract research and contract manufacturing organizations, hospitals, universities and government agencies.
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Fundamentals · Analysis method
Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis ↓
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Charles River Laboratories · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 18, 2026.
One-off effect in profit – prior-year figures are only partly comparable.
unusually high profit in quarter Q3/26 (net margin 33.9%).
Investor typeInvestor type (“lens”)You choose which style comes first: dividends, valuation, growth, quality or trading. Screener and stock page then show suggestions and “For you first”, with an account also matching columns and order. The lens unlocks nothing and changes no matches.Example: Lens “Dividends” → on the stock page first the streak without a cut, growth and cover of the dividend.More in the Academy: Guide fundamental analysis
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
–no data: Gross margin above 40%not stated in the SEC filings
✗not met: Operating margin above 15%0.6%
✗not met: Net margin above 10%−3.6%
✗not met: Return on equity above 15%−4.6%
✓met: Free cash flow margin above 10%12.9%
✗not met: Profit in each of the last 5 fiscal years4 of 5
✓met: Free cash flow positive in each of the last 3 fiscal years3 of 3
✓met: Equity ratio above 30%44.4%
Operating margin
0.6%Fiscal year 2025
All17weak
Rank 17 of 100: higher than 17% of 470 peers (All). weak.
Sector12weak
Rank 12 of 100: higher than 12% of 54 peers (Sector). weak.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
−3.6%Fiscal year 2025
All10weak
Rank 10 of 100: higher than 10% of 584 peers (All). weak.
Sector9weak
Rank 9 of 100: higher than 9% of 63 peers (Sector). weak.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
−4.6%Fiscal year 2025
All10weak
Rank 10 of 100: higher than 10% of 544 peers (All). weak.
Sector10weak
Rank 10 of 100: higher than 10% of 54 peers (Sector). weak.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
Return on assets
−2.0%Fiscal year 2025 (total assets at year end)
All10weak
Rank 10 of 100: higher than 10% of 594 peers (All). weak.
Sector10weak
Rank 10 of 100: higher than 10% of 63 peers (Sector). weak.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
Equity ratio
44.4%Fiscal year 2025
All62medium
Rank 62 of 100: higher than 62% of 595 peers (All). medium.
Sector52medium
Rank 52 of 100: higher than 52% of 63 peers (Sector). medium.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
12.9%Fiscal year 2025
All54medium
Rank 54 of 100: higher than 54% of 465 peers (All). medium.
Sector42medium
Rank 42 of 100: higher than 42% of 61 peers (Sector). medium.
Median Health Care: 14.5%
Free cash flow divided by revenue.
Free cash flow
518.5M USDFiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 2 of 7 met
✗not met: Over 3 years, revenue grew by more than 5% per year+0.3%
✓met: Over 5 years, revenue grew by more than 5% per year+6.5%
✓met: Over 10 years, revenue grew by more than 5% per year+11.4%
✗not met: Over 3 years, EPS grew by more than 5% per yearno earnings per share in the last fiscal year
✗not met: Over 5 years, EPS grew by more than 5% per yearno earnings per share in the last fiscal year
✗not met: Revenue rose in at least 4 of the last 5 fiscal years3 of 5
✗not met: Revenue rose in the last fiscal year−0.9%
Revenue growth 3 years
+0.3%per year
All22weak
Rank 22 of 100: higher than 22% of 578 peers (All). weak.
Sector20weak
Rank 20 of 100: higher than 20% of 62 peers (Sector). weak.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+6.5%per year
All37medium
Rank 37 of 100: higher than 37% of 549 peers (All). medium.
Sector39medium
Rank 39 of 100: higher than 39% of 60 peers (Sector). medium.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+11.4%per year
All77strong
Rank 77 of 100: higher than 77% of 412 peers (All). strong.
Sector73strong
Rank 73 of 100: higher than 73% of 50 peers (Sector). strong.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
Dividend 0 of 1 met · 6 without data
✗not met: Pays a dividendno dividend per share reported for the last fiscal year
–no data: Payout ratio at most 60% of earningspays no dividend
–no data: Dividend paid in each of the last 5 fiscal yearspays no dividend
–no data: Dividend per share never lowered in the last 5 fiscal yearspays no dividend
–no data: Dividend per share higher than 5 years agopays no dividend
–no data: Free cash flow per share covers the dividendpays no dividend
–no data: Dividends paid over the last 5 years covered by free cash flowpays no dividend
Financial strength 5 of 6 met
✗not met: Piotroski F-Score at least 7 of 93 of 7 · 2 without data
✓met: Long-term debt no higher than equity0.68
✓met: Current assets cover current liabilities1.29
✓met: Positive equity3.2B USD
✓met: In 5 years, share count up by at most 5%−2.1%
✓met: Free cash flow positive in the last fiscal year518.5M USD
Piotroski F-Score
3 of 7Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.68at fiscal year end
All47medium
Rank 47 of 100: lower than 47% of 486 peers (All). medium.
Sector45medium
Rank 45 of 100: lower than 45% of 50 peers (Sector). medium.
Median Health Care: 0.66
Long-term financial debt divided by equity.
Liquidity (current ratio)
1.29at fiscal year end
All48medium
Rank 48 of 100: higher than 48% of 513 peers (All). medium.
Sector33medium
Rank 33 of 100: higher than 33% of 63 peers (Sector). medium.
Median Health Care: 1.58
Current assets divided by current liabilities.
Change in share count
−2.1%in 5 years
All46medium
Rank 46 of 100: lower than 46% of 507 peers (All). medium.
Sector40medium
Rank 40 of 100: lower than 40% of 59 peers (Sector). medium.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
✗not met: Profit in the last fiscal year (positive return on assets)
✓met: Positive operating cash flow
✗not met: Return on assets higher than the prior year
✓met: Operating cash flow higher than net income
✗not met: Long-term debt relative to total assets fell
✗not met: Liquidity (current assets / current liabilities) rose
–no data: No additional shares (diluted share count did not rise)
–no data: Gross margin higher than the prior year
✓met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
Light yellow: Revenue grew over 5 years (+6.5% per year), more slowly than the sector median.
Light red: Loss in the last fiscal year.
Light yellow: Debt higher than usual in the sector.
Light yellow: Profit in 9 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
02B4B6B
2016Fiscal year 2016 (Dec 27, 2015 – Dec 31, 2016): Revenue 1.7B USD · Net income 154.8M USD · Net margin 9.2%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 30, 2017): Revenue 1.9B USD · Net income 123.4M USD · Net margin 6.6%
2018Fiscal year 2018 (Dec 31, 2017 – Dec 29, 2018): Revenue 2.3B USD · Net income 226.4M USD · Net margin 10.0%
2019Fiscal year 2019 (Dec 30, 2018 – Dec 28, 2019): Revenue 2.6B USD · Net income 252.0M USD · Net margin 9.6%
2020Fiscal year 2020 (Dec 29, 2019 – Dec 26, 2020): Revenue 2.9B USD · Net income 364.3M USD · Net margin 12.5%
2021Fiscal year 2021 (Dec 27, 2020 – Dec 25, 2021): Revenue 3.5B USD · Net income 391.0M USD · Net margin 11.0%
2022Fiscal year 2022 (Dec 26, 2021 – Dec 31, 2022): Revenue 4.0B USD · Net income 486.2M USD · Net margin 12.2%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 30, 2023): Revenue 4.1B USD · Net income 474.6M USD · Net margin 11.5%
2024Fiscal year 2024 (Dec 31, 2023 – Dec 28, 2024): Revenue 4.0B USD · Net income 22.2M USD · Net margin 0.5%
2025Fiscal year 2025 (Dec 29, 2024 – Dec 27, 2025): Revenue 4.0B USD · Net income −144.3M USD · Net margin −3.6%
Margin
9.2%6.6%10.0%9.6%12%11%12%11%0.5%−3.6%
RevenueNet incomeNet margin (below)in USD
−500M0500M1B1.5B
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 30, 2023): Revenue 1.0B USD · Net income 187.1M USD · Net margin 18.5% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Dec 31, 2023 – Mar 30, 2024): Revenue 1.0B USD · Net income 73.0M USD · Net margin 7.2%
Q2/24Quarter Q2/24 (Mar 31, 2024 – Jun 29, 2024): Revenue 1.0B USD · Net income 94.1M USD · Net margin 9.2%
Q3/24Quarter Q3/24 (Jun 30, 2024 – Sep 28, 2024): Revenue 1.0B USD · Net income 69.7M USD · Net margin 6.9%
Q4/24Quarter Q4/24 (Sep 29, 2024 – Dec 28, 2024): Revenue 1.0B USD · Net income −214.5M USD · Net margin −21.4% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Dec 29, 2024 – Mar 29, 2025): Revenue 984.2M USD · Net income 25.5M USD · Net margin 2.6%
Q2/25Quarter Q2/25 (Mar 30, 2025 – Jun 28, 2025): Revenue 1.0B USD · Net income 52.3M USD · Net margin 5.1%
Q3/25Quarter Q3/25 (Jun 29, 2025 – Sep 27, 2025): Revenue 1.0B USD · Net income 54.4M USD · Net margin 5.4%
Q4/25Quarter Q4/25 (Sep 28, 2025 – Dec 27, 2025): Revenue 994.2M USD · Net income −276.6M USD · Net margin −27.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Dec 28, 2025 – Mar 28, 2026): Revenue 995.8M USD · Net income −14.8M USD · Net margin −1.5%
Q2/26Quarter Q2/26 (Mar 29, 2026 – Jun 27, 2026): Revenue 1.0B USD · Net income −1.5M USD · Net margin −0.1%
Q3/26Quarter Q3/26 (Jun 28, 2026 – Sep 26, 2026): Revenue 982.7M USD · Net income 333.1M USD · Net margin 33.9%
Margin
18%7.2%9.2%6.9%−21%2.6%5.1%5.4%−28%−1.5%−0.1%34%
Earnings per shareUSD per share
−5.0005.0010
2016Fiscal year 2016 (Dec 27, 2015 – Dec 31, 2016): Earnings per share 3.23 USD
2017Fiscal year 2017 (Jan 1, 2017 – Dec 30, 2017): Earnings per share 2.54 USD
2018Fiscal year 2018 (Dec 31, 2017 – Dec 29, 2018): Earnings per share 4.62 USD
2019Fiscal year 2019 (Dec 30, 2018 – Dec 28, 2019): Earnings per share 5.07 USD
2020Fiscal year 2020 (Dec 29, 2019 – Dec 26, 2020): Earnings per share 7.20 USD
2021Fiscal year 2021 (Dec 27, 2020 – Dec 25, 2021): Earnings per share 7.60 USD
2022Fiscal year 2022 (Dec 26, 2021 – Dec 31, 2022): Earnings per share 9.48 USD
2023Fiscal year 2023 (Jan 1, 2023 – Dec 30, 2023): Earnings per share 9.22 USD
2024Fiscal year 2024 (Dec 31, 2023 – Dec 28, 2024): Earnings per share 0.20 USD
2025Fiscal year 2025 (Dec 29, 2024 – Dec 27, 2025): Earnings per share −2.91 USD
Earnings per shareUSD per share
02.004.006.008.00
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 30, 2023): Earnings per share not reported separately for Q4
Q1/24Quarter Q1/24 (Dec 31, 2023 – Mar 30, 2024): Earnings per share 1.30 USD
Q2/24Quarter Q2/24 (Mar 31, 2024 – Jun 29, 2024): Earnings per share 1.74 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Dec 29, 2024 – Dec 27, 2025): Revenue 4.0B USD · Net income −144.3M USD · Net margin −3.6%
How has it gone since the last annual report?
Trailing 12 months and quarters
Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Revenue in the quarter to Sep 2026 −2.2% vs. the same quarter a year earlier.
Revenue 12 months vs. prior 12Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Free cash flow margin 12 monthsFree cash flowCash from operations minus investment in property, plant and equipment. It shows how much money is left over – for repaying debt, dividends or share repurchases.Example: Operating cash flow 120 million euros, investments 45 million euros → free cash flow 75 million euros.More in the Academy: Guide fundamental analysis
10.0%
Fiscal year 2025: 12.9%
More depth
Calculation of the 12 months to Sep 26, 2026
Revenue: fiscal year to Dec 27, 2025 4.0B USD + year to date to Sep 26, 2026 3.0B USD − same period a year earlier to Sep 27, 2025 3.0B USD = 4.0B USD
Net income: fiscal year to Dec 27, 2025 −144.3M USD + year to date to Sep 26, 2026 316.7M USD − same period a year earlier to Sep 27, 2025 132.2M USD = 40.2M USD
Operating cash flow: fiscal year to Dec 27, 2025 737.6M USD + year to date to Sep 26, 2026 474.9M USD − same period a year earlier to Sep 27, 2025 590.1M USD = 622.4M USD
Capital expenditure: fiscal year to Dec 27, 2025 219.2M USD + year to date to Sep 26, 2026 133.8M USD − same period a year earlier to Sep 27, 2025 130.2M USD = 222.8M USD
By quarter (latest first, amounts in USD)
Quarter
Revenue
vs. year ago
Net income
Margin
Jul–Sep 26
982.7M
−2.2%
333.1M
33.9%
Apr–Jun 26
1.0B
−2.7%
−1.5M
−0.1%
Jan–Mar 26
995.8M
+1.2%
−14.8M
−1.5%
Oct–Dec 25*
994.2M
−0.8%
−276.6M
−27.8%
Jul–Sep 25
1.0B
−0.5%
54.4M
5.4%
Apr–Jun 25
1.0B
+0.6%
52.3M
5.1%
Jan–Mar 25
984.2M
−2.7%
25.5M
2.6%
Oct–Dec 24*
1.0B
−1.1%
−214.5M
−21.4%
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 26, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Earnings quality
There was no profit in fiscal year 2025; interest is thinly covered.
Cash flow ÷ profitCash flow ÷ profitOperating cash flow divided by group profit. From 1.0, at least as much cash came in as profit was reported; below that, profit may sit in receivables or inventories, and non-cash gains or one-off payments also push the ratio down. Depreciation and stock-based pay lift it.Example: Operating cash flow €120m, group profit €100m → 1.20x.More in the Academy: Lesson earnings quality
–
no profit in fiscal year 2025
Interest coverageInterest coverageOperating income divided by interest expense: how many times the core business earns its interest. From 5x we count interest as well covered, below 2x as thinly covered.Example: Operating income €50m, interest expense €5m → 10.0x.More in the Academy: Lesson earnings quality
0.2x
25
well covered from 5 · 3 years: 2.4x
Tax rateTax rateIncome taxes divided by profit before tax, in percent. If the SEC data lack it, we approximate it as group profit plus taxes; minority interests, discontinued operations, one-off items and tax credits can shift the rate.Example: Taxes €21m, net income €79m → 21 : 100 = 21%.More in the Academy: Lesson earnings quality
–
no profit before tax · 3 years: 36.8%
More depth
Calculation for fiscal year 2025
Operating cash flow 737.6M USD ÷ group profit incl. minority interests −142.2M USD = no ratio (no profit)
Taxes 42.7M USD ÷ profit before tax −99.5M USD = no rate (no profit before tax)
By fiscal year
FY
Cash flow ÷ profit
Interest coverage
Tax rate
2025
–
0.2x
–
2024
over 10x
1.8x
72.8%
2023
1.42x
4.5x
17.4%
2022
1.26x
11.0x
20.9%
2021
1.91x
8.0x
17.0%
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
Consistency
In 10 fiscal years one loss year and 2 years with lower revenue.
Loss yearsLoss yearsFiscal years that ended with a loss on the bottom line (net income below zero). Few loss years over a long period show how evenly a company has earned so far – they say nothing about the future.Example: Loss only in fiscal year 2020 → 1 of 10.More in the Academy: Lesson revenue, profit and margin
1 of 10
net income below zero
Years with lower revenueYear with lower revenueA fiscal year in which revenue was lower than in the prior year. Only years for which the prior year’s revenue is also reported are counted.Example: Revenue 100 → €96m → one year with lower revenue.More in the Academy: Lesson revenue, profit and margin
2 of 10
revenue below the prior year
Net margin rangeNet margin rangeHighest minus lowest net margin of the fiscal years shown, in percentage points. A small range means the share of profit in revenue stayed similar over the years.Example: Net margins between 18.2% and 26.4% → range 8.2 percentage points.More in the Academy: Lesson revenue, profit and margin
16.1 percentage points
from −3.6% to 12.5%
▾▾20162025Net margin by fiscal year · ▾ revenue below the prior yearMore depth
By fiscal year
FY
Revenue vs. prior year
Net margin
2025
−0.9%
−3.6%
2024
−1.9%
0.5%
2023
+3.9%
11.5%
2022
+12.3%
12.2%
2021
+21.1%
11.0%
2020
+11.5%
12.5%
2019
+15.7%
9.6%
2018
+22.0%
10.0%
2017
+10.5%
6.6%
2016
+23.3%
9.2%
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 0.6 USD operating income remained.
2016Fiscal year 2016: Operating cash flow 316.9M USD · Capital expenditure 55.3M USD · Free cash flow 261.6M USD
2017Fiscal year 2017: Operating cash flow 318.1M USD · Capital expenditure 82.4M USD · Free cash flow 235.6M USD
2018Fiscal year 2018: Operating cash flow 441.1M USD · Capital expenditure 140.1M USD · Free cash flow 301.1M USD
2019Fiscal year 2019: Operating cash flow 480.9M USD · Capital expenditure 140.5M USD · Free cash flow 340.4M USD
2020Fiscal year 2020: Operating cash flow 546.6M USD · Capital expenditure 166.6M USD · Free cash flow 380.0M USD
2021Fiscal year 2021: Operating cash flow 760.8M USD · Capital expenditure 228.8M USD · Free cash flow 532.0M USD
2022Fiscal year 2022: Operating cash flow 619.6M USD · Capital expenditure 324.7M USD · Free cash flow 294.9M USD
2023Fiscal year 2023: Operating cash flow 683.9M USD · Capital expenditure 318.5M USD · Free cash flow 365.4M USD
2024Fiscal year 2024: Operating cash flow 734.6M USD · Capital expenditure 233.0M USD · Free cash flow 501.6M USD
2025Fiscal year 2025: Operating cash flow 737.6M USD · Capital expenditure 219.2M USD · Free cash flow 518.5M USD
Share count
The share count fell in 5 years by 2.1% (mostly through share repurchases).
Diluted share count
020M40M60M
2016Fiscal year 2016: Diluted share count 48.0M
2017Fiscal year 2017: Diluted share count 48.6M
2018Fiscal year 2018: Diluted share count 49.0M
2019Fiscal year 2019: Diluted share count 49.7M
2020Fiscal year 2020: Diluted share count 50.6M
2021Fiscal year 2021: Diluted share count 51.4M
2022Fiscal year 2022: Diluted share count 51.3M
2023Fiscal year 2023: Diluted share count 51.5M
2024Fiscal year 2024: Diluted share count not available
2025Fiscal year 2025: Diluted share count 49.6M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Metrics chart
Metrics chartUp to three metrics stacked, each with its own axis, over the same fiscal years. Optionally a second stock (dashed or hatched) and today’s sector median as a mark in the latest year – we do not have earlier medians.Example: Revenue rises, net margin falls, share count falls → more business, less profit per unit of revenue, fewer shares (mostly through buybacks).More in the Academy: Guide fundamental analysis
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
No annual figures for this stock: Dividend per share, Payout ratio (earnings), Payout ratio (free cash flow).
Source: SEC filings, fiscal years up to Dec 27, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
Dividend at a glance
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
Valuation against its own history
Valuation against its own historyWhere P/E, P/S or price/free cash flow stands today compared with the median of the company’s own last 5 fiscal years, in percent. Up to 10% deviation counts as “about at the median”. Describes only the position, not a judgement on an appropriate price.Example: P/E today 22, own 5-year median 27 → 22 ÷ 27 − 1 = −18.5%, so below the median.More in the Academy: Lesson cheaper or pricier than usual?
There is no comparison for the P/E: the last fiscal year ended with a loss.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation.Sign up free
Source: SEC filings and our daily candles
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividend per share
nonepays no dividend
To shareholders (5 years)
583.4M USD100% through repurchases
Share count over 5 years
−2.1%fewer shares – each share is a larger stake
What goes back to shareholders
Over 5 years, 583.4M USD went back to shareholders, 100% of it through share repurchases. That is 26% of the free cash flow of those years.
2016Fiscal year 2016: Dividends paid not available · Share repurchases 12.3M USD · New shares issued (including employee plans) not available · Free cash flow 261.6M USD
2017Fiscal year 2017: Dividends paid not available · Share repurchases 106.9M USD · New shares issued (including employee plans) not available · Free cash flow 235.6M USD
2018Fiscal year 2018: Dividends paid not available · Share repurchases 13.8M USD · New shares issued (including employee plans) not available · Free cash flow 301.1M USD
2019Fiscal year 2019: Dividends paid not available · Share repurchases 18.1M USD · New shares issued (including employee plans) not available · Free cash flow 340.4M USD
2020Fiscal year 2020: Dividends paid not available · Share repurchases 24.0M USD · New shares issued (including employee plans) not available · Free cash flow 380.0M USD
2021Fiscal year 2021: Dividends paid not available · Share repurchases 40.7M USD · New shares issued (including employee plans) not available · Free cash flow 532.0M USD
2022Fiscal year 2022: Dividends paid not available · Share repurchases 38.7M USD · New shares issued (including employee plans) not available · Free cash flow 294.9M USD
2023Fiscal year 2023: Dividends paid not available · Share repurchases 24.2M USD · New shares issued (including employee plans) not available · Free cash flow 365.4M USD
2024Fiscal year 2024: Dividends paid not available · Share repurchases 119.2M USD · New shares issued (including employee plans) not available · Free cash flow 501.6M USD
2025Fiscal year 2025: Dividends paid not available · Share repurchases 360.7M USD · New shares issued (including employee plans) not available · Free cash flow 518.5M USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.Log in
Sector comparison
Charles River Laboratories next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
Sector comparison CRL, sector Health Care; last row: sector median
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light yellow: below sector
+6.5%per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 6.5% per year on average, but more slowly than the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light gray: not computable
–per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 3.59 USD. Five years ago the margin was 12.5%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light yellow: higher than sector
0.76latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.76 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light yellow: 1 loss year
9 of 10fiscal years with a profit
What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
4.0B USD
Revenue vs. prior year
−0.9%
Net income (FY)
−144.3M USD
Net income vs. prior year
−750.1%
EPS (FY)
-2.91 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 27, 2025 · 10-K filed Feb 18, 2026 · Balance sheet Sep 26, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 27, 2025
4.0B
−144.3M
−3.6%
−2.91
–
–
2024
Dec 28, 2024
4.0B
22.2M
0.5%
0.20
–
–
2023
Dec 30, 2023
4.1B
474.6M
11.5%
9.22
–
–
2022
Dec 31, 2022
4.0B
486.2M
12.2%
9.48
–
–
2021
Dec 25, 2021
3.5B
391.0M
11.0%
7.60
–
–
2020
Dec 26, 2020
2.9B
364.3M
12.5%
7.20
–
–
2019
Dec 28, 2019
2.6B
252.0M
9.6%
5.07
–
–
2018
Dec 29, 2018
2.3B
226.4M
10.0%
4.62
–
–
2017
Dec 30, 2017
1.9B
123.4M
6.6%
2.54
–
–
2016
Dec 31, 2016
1.7B
154.8M
9.2%
3.23
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q3/26
Sep 26, 2026
982.7M
333.1M
33.9%
6.86
–
–
Q2/26
Jun 27, 2026
1.0B
−1.5M
−0.1%
−0.03
–
–
Q1/26
Mar 28, 2026
995.8M
−14.8M
−1.5%
−0.30
–
–
Q4/25*
Dec 27, 2025
994.2M
−276.6M
−27.8%
–
–
–
Q3/25
Sep 27, 2025
1.0B
54.4M
5.4%
1.10
–
–
Q2/25
Jun 28, 2025
1.0B
52.3M
5.1%
1.06
–
–
Q1/25
Mar 29, 2025
984.2M
25.5M
2.6%
0.50
–
–
Q4/24*
Dec 28, 2024
1.0B
−214.5M
−21.4%
–
–
–
Q3/24
Sep 28, 2024
1.0B
69.7M
6.9%
1.33
–
–
Q2/24
Jun 29, 2024
1.0B
94.1M
9.2%
1.74
–
–
Q1/24
Mar 30, 2024
1.0B
73.0M
7.2%
1.30
–
–
Q4/23*
Dec 30, 2023
1.0B
187.1M
18.5%
–
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Aug 25, 2026Foster James CDirectorOpen-market sale · 10b5-1 plan33,561 shares · $10.1M · SEC
Aug 19, 2026Parisotto Shannon MOfficerOpen-market sale · 10b5-1 plan2,039 shares · $599.7K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Which superinvestors hold Charles River Laboratories?
Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
Trend score –
We do not calculate a trend score for symbols in the extended universe.
Volatility and trend strength
ADX 14 (trend strength)–
Price change 60 days–
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.